[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hims & Hers Health Inc (HIMS)

Hims & Hers Health Inc (HIMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices

Hims & Hers (HIMS) stock tanked on July 29 after the Federal Trade Commission, alongside Utah and Los Angeles County, filed a lawsuit against the telehealth provider. The regulators allege HIMS misled consumers about recurring subscriptions, deliberately obstructed cancellations, and illegally shared private patient health data with ad platforms like Meta (META) and Snap (SNAP).

Hims & Hers shares have rebounded slightly on July 30 and are now down about 32% versus their recent high. 

Fundamentals

See More
  • Market Capitalization, $K 5,786,450
  • Shares Outstanding, K 231,458
  • Annual Sales, $ 2,348 M
  • Annual Income, $ 128,370 K
  • EBIT $ -31 M
  • EBITDA $ 26 M
  • 60-Month Beta 2.35
  • Price/Sales 2.89
  • Price/Cash Flow 35.03
  • Price/Book 15.16

Options Overview Details

View History
  • Implied Volatility 107.31% (-0.50%)
  • Historical Volatility 93.89%
  • IV Percentile 83%
  • IV Rank 70.65%
  • IV High 127.22% on 10/16/25
  • IV Low 59.38% on 12/31/25
  • Expected Move (DTE 1) 1.11 (4.17%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 46,475
  • Volume Avg (30-Day) 100,700
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 919,159
  • Open Int (30-Day) 936,164
  • Expected Range 25.40 to 27.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.07
  • Number of Estimates 3
  • High Estimate $-0.01
  • Low Estimate $-0.16
  • Prior Year $0.17
  • Growth Rate Est. (year over year) -141.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.31 +9.23%
on 07/30/26
39.05 -32.00%
on 07/06/26
-8.11 (-23.41%)
since 06/30/26
3-Month
21.53 +23.34%
on 05/19/26
39.05 -32.00%
on 07/06/26
-0.61 (-2.26%)
since 04/30/26
52-Week
13.74 +93.27%
on 02/24/26
70.43 -62.30%
on 07/31/25
-38.97 (-59.48%)
since 07/30/25

Most Recent Stories

More News
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the...

HIMS : 26.56 (+6.24%)
HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

META : 530.16 (-9.47%)
HIMS : 26.56 (+6.24%)
NVO : 51.03 (-1.07%)
SNAP : 4.68 (-1.06%)
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS ) investors concerning the Company’s possible...

HIMS : 26.56 (+6.24%)
2 Unprofitable Stocks for Long-Term Investors and 1 We Ignore

2 Unprofitable Stocks for Long-Term Investors and 1 We Ignore

SFIX : 4.08 (-3.77%)
FCEL : 22.58 (+24.89%)
HIMS : 26.56 (+6.24%)
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS ) on behalf of investors concerning the Company’s...

HIMS : 26.56 (+6.24%)
Oil prices jump, while the Dow drops more than 1,100 as sinking AI stocks drag Wall Street lower

Oil prices got back to jumping, while sinking technology stocks dragged Wall Street lower amid uncertainty about what the Federal Reserve will do to get high inflation under control

KLAC : 181.03 (+6.37%)
AMAT : 494.75 (+13.36%)
META : 530.16 (-9.47%)
NVDA : 192.81 (+1.47%)
AAPL : 332.19 (-1.77%)
KO : 88.10 (-1.10%)
$SPX : 7,412.09 (+1.31%)
HIMS : 26.56 (+6.24%)
MU : 851.21 (+15.18%)
$IUXX : 28,017.08 (+3.03%)
MSFT : 453.66 (+16.16%)
SBUX : 107.62 (+3.34%)
Hims & Hers Responds to FTC Lawsuit

Hims & Hers Health, Inc. (NYSE: HIMS) responded to the lawsuit filed today by the Federal Trade Commission (FTC): This lawsuit disregards substantial evidence we provided the FTC during its nearly...

HIMS : 26.56 (+6.24%)
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder

Hims & Hers shares crash as FDA panel votes against emideltide’s addition to the 503A Bulks List. Here’s what the news means for HIMS stock.

HIMS : 26.56 (+6.24%)
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

TXG : 48.18 (+4.02%)
HIMS : 26.56 (+6.24%)
RGEN : 142.77 (+1.09%)
WST : 337.21 (-0.07%)
1 Cash-Producing Stock to Target This Week and 2 Facing Headwinds

1 Cash-Producing Stock to Target This Week and 2 Facing Headwinds

HIMS : 26.56 (+6.24%)
DBD : 74.87 (-0.40%)
HD : 332.46 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Hims & Hers Health Inc. is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling medical care for numerous conditions related to mental health, sexual health, dermatology, primary care and more. Hims & Hers Health Inc., formerly known as Oaktree...

See More

Key Turning Points

3rd Resistance Point 31.98
2nd Resistance Point 30.47
1st Resistance Point 27.74
Last Price 26.59
1st Support Level 23.50
2nd Support Level 21.99
3rd Support Level 19.26

See More

52-Week High 70.43
Fibonacci 61.8% 48.77
Fibonacci 50% 42.08
Fibonacci 38.2% 35.40
Last Price 26.59
52-Week Low 13.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.